Dergiler / Medicine Science / 2020 / Cilt: 9 - Sayı: 3

Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia

Sayfa
530–534
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We believe that future molecular studies on this subject may further elucidate the association between carcinoma development and the expression of these molecules, leading to new therapeutic targets in the treatment of PCa.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Disruption of the E cadherin mediated complex due to loss or depletion of E cadherin results in epithelial abnormalities and serious developmental impairment in various tissues and organs.
📊
Temel Bulgular & Veri:Immunohistochemical staining for E cadherin and β catenin was performed in 59 patients diagnosed with PCa and 30 patients with BPH.
💡
Sonuç & Katkı:We believe that future molecular studies on this subject may further elucidate the association between carcinoma development and the expression of these molecules, leading to new therapeutic targets in the treatment of PCa.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Disruption of the E cadherin mediated complex due to loss or depletion of E cadherin results in epithelial abnormalities and serious developmental impairment in various tissues and organs. The present study aims to determine E cadherin and β catenin expression in patients diagnosed with benign prostatic hyperplasia (BPH) and prostate carcinoma (PCa) based on Gleason scores and investigate the association of these proteins with PSA levels and Gleason scoring. Immunohistochemical staining for E cadherin and β catenin was performed in 59 patients diagnosed with PCa and 30 patients with BPH. Mean E cadherin expression was 3.00 in patients diagnosed with BPH and 2.38±0.5 in patients with PCa, with a statistically significant difference between these values (p<0.001). Comparison of PCa cases with PSA <10 versus those with PSA ≥10 revealed significantly reduced β catenin expression in the group with PSA levels ≥10 (p<0.001). Loss of E cadherin and β catenin is known to contribute to the pathogenesis of PCa. We believe that future molecular studies on this subject may further elucidate the association between carcinoma development and the expression of these molecules, leading to new therapeutic targets in the treatment of PCa.

🔖

Bu Makaleye Atıf Yap

ARSLAN, A. İ., KARABAĞ, S., AKGÜL, M., YILDIRIM, İ. (2020). Immunohistochemical expression of E-Cadherin and β-catenin in prostate adenocarcinoma and benign prostate hyperplasia. Medicine Science, Cilt: 9 - Sayı: 3, 530–534. https://ajindex.com/articles/276896

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424
  2. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. EAU, Arnhem, The Netherlands; 2018. https://uroweb.org/ wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-ProstateCancer-large-text-V2.pdf 3. Tinay İ, Akgül HM, Tanıdır Y. Metabolik Sendrom ve Benign Prostat Hiperplazisi: Güncelleme. Üroonkoloji Bülteni. 2014;13:206-9
  3. Akgül M, Üren N, Yaman A, Baykan Ö, et al. The Relationship Between Vitamine D Gene Polymorphysms and the Diagnosis of Prostate Cancer at Patients with High PSA Value. Bulletin of Urooncology. 2020
  4. Silva RS, Lombardi AP, Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. International Journal of Biochemistry and Cell Biology. 2018;96:40–50
  5. Musalam A, Andarawi M, Osman M, et al. Alterations of COX-2, HER-2/ neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings. Am J Transl Res. 2019;11:1653-67
  6. Olson A, Le V, Aldah J, et al. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. PLoS Genet. 2019;15:e1008451
  7. Abdallah RA, Abdou AG, Abdelwahed M, et al. Immunohistochemical Expression of E‑ and N‑Cadherin in Nodular Prostatic Hyperplasia and Prostatic Carcinoma. J Microsc Ultrastruct. 2019;7:19-27
  8. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2005;23:402–6 10. Kypta R, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9,418–28
  9. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2005;23:402–6
  10. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837–51
  11. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997;275:1784–7
  12. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications